Clinical trialNARecruiting
Prospective Monocentric Clinical-biological Database
Establishment of a Monocentric and Prospective Clinico-biological Database in Patients With Pancreatic Adenocarcinoma
- Outcome
- Ongoing
- Phase
- NA
- Status
- Recruiting
- Study type
- Interventional
- Start
- 15 May 2019
- Expected end
- June 2034
- Enrollment
- 120 participants
- Sites
- 1
- Primary outcomes
- Proportion of patients who gave their consent to participate in the study
- Sponsor
- Other
- Results posted
- No
- Last update
- 12 February 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 5
- BackgroundTargeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inh… DOI 10.1016/j.canlet.2018.06.023↗
- BackgroundPancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. DOI 10.2147/dddt.s60328↗
- BackgroundPancreatic cancer: from state-of-the-art treatments to promising novel therapies. DOI 10.1038/nrclinonc.2015.53↗
- BackgroundProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the Un… DOI 10.1158/0008-5472.can-14-0155↗
- BackgroundPreclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. DOI 10.1038/onc.2013.487↗